Sebela Pharmaceuticals Development LLC

Pharma

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Activity

Key Events

Dec 11, 2018FDASporanox — TOLSURA

Nov 20, 2017TrialSafety and Efficacy Study of an Edible Colonoscopy Preparation

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Paxil2 patentsAug 4, 2026 SporanoxOct 3, 2028 PaxilApr 6, 2029 Sporanox5 patentsJun 21, 2033

Regulatory

Regulatory Timeline

19922 events

FDADec 29

Paxil — PAXIL

Application NDA020031 (NDA)

FDASep 11

Sporanox — SPORANOX

Application NDA020083 (NDA)

19972 events

FDAJun 25

Paxil — PAXIL

Application NDA020710 (NDA)

FDAFeb 21

Sporanox — SPORANOX

Application NDA020657 (NDA)

19981 event

FDAOct 9

Paxil — PAXIL

Application NDA020885 (NDA)

19992 events

FDAMar 30

Sporanox — SPORANOX

Application NDA020966 (NDA)

FDAFeb 16

Paxil — PAXIL CR

Application NDA020936 (NDA)

20031 event

FDAJul 3

Paxil — PEXEVA

Application NDA021299 (NDA)

20101 event

FDAApr 29

Sporanox — ONMEL

Application NDA022484 (NDA)

20131 event

FDAJun 28

Paxil — BRISDELLE

Application NDA204516 (NDA)

20181 event

FDADec 11

Sporanox — TOLSURA

Application NDA208901 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)